Investigating how decorin and MRI can improve treatment for recurrent glioblastoma
Official title: Role of decorin and diffusion MRI in anti-VEGF efficacy for recurrent glioblastoma
Funded at University of California Los Angeles · NIH-11054702 · Data updated 2026-11-12
This study is looking at how a special protein and MRI scans can help doctors figure out which patients with recurring glioblastoma might benefit the most from a treatment that blocks blood vessel growth in tumors, with the goal of improving outcomes for those patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | April 1, 2022 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $607,842 |
| NIH project number | 5R01CA270027-04 |
| Project ID | NIH-11054702 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with recurrent glioblastoma who are considering or currently receiving bevacizumab treatment.
✕Less likely to help
Patients with glioblastoma who are not experiencing recurrence or those who are not eligible for bevacizumab may not benefit from this research.
What this research studies
This research focuses on recurrent glioblastoma, a highly aggressive brain cancer with limited treatment options. It aims to explore the role of decorin and diffusion MRI in enhancing the effectiveness of bevacizumab, a drug that inhibits blood vessel growth in tumors. By identifying imaging biomarkers that predict which patients will benefit from this treatment, the study seeks to improve patient outcomes and guide future therapies. The approach involves analyzing MRI characteristics to stratify patients based on their likelihood of responding to anti-VEGF therapy.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment strategies for patients with recurrent glioblastoma, potentially improving survival rates.
How similar studies have gone: Previous studies have shown promising results using diffusion MRI as a predictive tool for treatment efficacy in glioblastoma, indicating that this approach has potential for success.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Ellingson, Benjamin M. — University of California Los Angeles
- Study coordinator: Ellingson, Benjamin M.
Related research
Other NIH-funded projects on the same topics.
-
Dual-hypoxia and proliferation PET biomarker for recurrent glioblastoma
A study using a special PET imaging approach to map oxygen-poor areas and cell growth in recurrent brain tumors to guide treatment decisions.
-
Sonodynamic therapy for recurrent glioblastoma using MRI-guided focused ultrasound and ALA
A new treatment combines a drug called 5-ALA with MRI-guided focused ultrasound to target recurrent glioblastoma tumors.
-
Targeting Fatty Acid Metabolism to Fight Brain Cancer (GBM)
A new treatment approach uses a repurposed drug to cut off the energy supply of glioblastoma tumors in the brain.
-
Giving immune checkpoint therapy before surgery for recurrent glioblastoma
This research gives an immune checkpoint drug before surgery to people with recurrent glioblastoma to help the immune system attack the tumor.
-
Decorin and MRI markers to predict response to anti-VEGF treatment in recurrent glioblastoma
This project looks at whether a protein called decorin and a type of MRI (diffusion MRI) can help predict which people with recurrent glioblastoma will benefit from anti-VEGF therapy like bevacizumab.
-
Using immune therapy before surgery for recurrent glioblastoma
This study is looking at how giving a special immune therapy before surgery can help patients with recurrent glioblastoma fight their tumors better, and it will compare the results to the usual treatments given after surgery.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.